Abstract: A process for isolating insulin which entails performing high-pressure liquid chromatography with pressure-stable acidic cation exchange material under a pressure of from 1.1 MPa to 40 MPa.

Abstract: Hirudin derivatives can be prepared by the selective enzymic replacement of a part of the molecule with an amino derivative. The hirudin derivatives are suitable for preparing pharmaceuticals having an anticoagulatory effect.

Abstract: A process for obtaining insulin having correctly linked cystine bridges from a corresponding proinsulin amino acid chain in the presence of mercaptan, chaotropic auxiliaries and at a pH of 10 to 11 is described, as well as the direct conversion of the proinsulin to insulin with the aid of enzymes and direct isolation of the insulin from the reaction mixture with the aid of hydrophobic adsorber resins.

Abstract: The present invention relates to hirudin derivatives which are formed from hirudin or the physiologically acceptable salt thereof and a carrier, to a process for the preparation thereof, and to the use thereof as thrombin inhibitor.

Abstract: A process is described for obtaining proinsulin possessing correctly linked cystine bridges from a corresponding proinsulin amino acid chain in the presence of mercaptan and chaotropic auxiliary agents and at a pH of 10 to 11, as well as its direct isolation from the reaction mixture using hydrophobic adsorber resins.

Abstract: A process for the production of an amorphous monospheric form of insulin derivatives is described, wherein the insulin derivative is dissolved in an n-propanol/buffer mixture at a pH of 4.5 to 6.5, an n-propanol content of more than 13% relative to water is established and the resulting solution is subsequently diluted with water.

Abstract: Mixed crystals composed of (a) unmodified insulin, des-Phe-B1 insulin, des-Thr-B30 (human) or des-Ala-B30 (pork, beef) insulin and (b) least one insulin having a basic modification at the C-terminal end of the B chain, preferably composed of human insulin and Arg-B31 human insulin and/or Arg.sub.2 -(B31-32) human insulin. These mixed crystals are obtained by crystallization from aqueous solution within a narrow pH range (from about 5.5 to about 6.9). The mixed crystals show a specific moderately prolonged profile and are suitable for the treatment of diabetes mellitus.

Abstract: The invention relates to a process for the preparation of an insulin derivative of the formula I ##STR1## in which R.sup.1 denotes H or H-Phe, R.sup.30 represents the radical of a naturally occurring L-aminoacid and R.sup.31 represents a physiologically acceptable organic group of neutral or basic character consisting of 1 to 3 .alpha.-aminoacids in which the terminal carboxyl function is present in the free form and which insulin derivative has an isoelectric point above 5.8, which comprises reacting an insulin of the formula I in which R.sup.30 denotes the radical of a genetically codable L-aminoacid and R.sup.31 represents OH or a protective group of the carboxyl function, with a peptide or aminoacid derivatives of the formula R-R.sup.30 -R.sup.31 consisting of 2 to 4 .alpha.-aminocacids, in which the terminal carboxyl function is in free form, in the presence of a trypsin-like endopeptidase at a pH value below the isoelectric point of the starting insulin.

Abstract: The invention relates to a process for the isolation and purification of .alpha.-interferons by (a) dissolution of the interferon-containing crude product in guandine. HCl solution and precipitation by dilution with water and/or (b) by chromatography on an HIC column under renaturing conditions.

Abstract: The invention relates to a process for the isolation and purification of .alpha.-interferons generated by plasmids from bacterial cultures which have been modified by genetic engineering, and of .alpha.-interferons from culture supernatants of induced mammalian cells, which comprises partition of appropriate crude substances containing interferon between an aqueous urea solution, which contains a surfactant, and a mixture of n-butanol and glacial acetic acid which contains water, and isolation of the purified .alpha.-interferons from the upper phase.

Abstract: A method for separating insulin or certain insulin derivatives from mixtures containing the same by chromatography of the mixture on a column filled with silica gel having a particle size between 40 and 500 microns with an eluant mixture comprising chloroform, methanol, water and triethylamine.

Abstract: The invention relates to a process for the preparation of peptides of the general formulaArg--Lys--S--Val--Yin which S denotes glutamic acid or .alpha.-aminoadipic acid and Y denotes tyrosine or tryptophan or esters or amides thereof, which comprises subjecting tetrapeptides of the formulaZ--Arg(Z'.sub.2)--Lys(Z')--S--(Bzl)--Val--OHin which Z' represents a protective group of the benzyl type, to a condensation reaction with corresponding tyrosine esters or amides or tryptophan esters or amides and removing the protective groups by hydrogenation. The invention furthermore relates to tetrapeptides as intermediate products of this process.

Abstract: The invention relates to cyclopeptides of the formula I ##STR1## in which A denotes Lys, D-Lys, Arg or D-Arg, B denotes Lys, D-Lys, Arg or D-Arg, C denotes Asp, D-Asp, Glu or D-Glu, U denotes Val or D-Val and D denotes Tyr, D-Tyr, Trp, D-Trp, Phe or D-Phe, 1 to 4 of the radicals A, B, C, U and D being in the L-configuration and the remaining radicals being in the D-configuration, processes for their preparation, their use and peptidic precursors and processes for their preparation.

Abstract: The invention relates to a process for the preparation of insulins from analogs of preproinsulins, which comprises reacting preproinsulin analogs, at a pH below the isoelectric point of the insulins in the presence of trypsin or a trypsin-like endopeptidase, with an ester of natural amino acids or their derivatives and then cleaving off the ester group and other protective groups which may optionally be present.

Abstract: What is disclosed is a method for making human insulin or modified human insulin from pig insulin or modified pig insulin by reacting the pig insulin starting material at a pH below its isoelectric point with an excess of a threonine ester in the presence of trypsin or a trypsin-like enzyme.

Abstract: A peptide of the formulaB.sub.1 --B.sub.2 --A.sub.1 --A.sub.2 --Xin whichB.sub.1 denotes a basic aminoacid,B.sub.2 denotes a basic aminoacid,A.sub.1 denotes an aromatic aminoacid,A.sub.2 denotes an aromatic aminoacid andX denotes an aminoacid in which the carboxyl group can be esterified, a process for the preparation thereof and the use thereof.

Abstract: The invention provides a nonapeptide of the formula IGlu-Asp-Ser-Ser-Ser-Thr-Gly-Trp-Asn-OH (I)a process for the preparation thereof and its use, furthermore intermediates for preparing a compound of the formula I.

Abstract: A process for the purification of secretin by chromatography on an alkylated dextran gel is disclosed, as is a method of its manufacture appropriate for preparing larger amounts of secretin.

Abstract: A process for the manufacture of human insulin by the condensation of porcine des-B.sub.23-30 octapeptide insulin with a peptide and subsequent splitting-off of the protective groups by treatment with trifluoroacetic acid or with alkali.

Abstract: A process for manufacture of insulin, analogs and derivatives thereof by treating an insulin compound wherein the A- and B-chains are linked by a bis-methionyl-carbonyl-bridge, with cyano bromide.